Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StratosPHere 2 trial of hydroxychloroquine and phenylbutyrate in BMPR2-associated pulmonary arterial hypertension
ISRCTN10304915Phase 2Recruiting
- Sponsor
- Papworth Hospital NHS Foundation Trust
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and Heritable Pulmonary Arterial Hypertension (HPAH) comparing Standard of care + hydroxychloroquine, Standard of care + phenylbutyrate and Standard of care + placebo (3 arms). Primary endpoint: Target engagement of the BMPR2 pathway. Started Dec 2023; status: recruiting.
02
Drugs
hydroxychloroquinesodium phenylbutyrate
03
Conditions
pulmonary arterial hypertension (PAH)Heritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on ISRCTN10304915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10304915.